Inflammatory markers in STelevation acute myocardial infarction

European Heart Journal: Acute Cardiovascular Care

Volumn 5, Issue 4, 2016, Pages 382-395

  Seropian, Ignacio M ^a   Sonnino, Chiara ^b,c   Van Tassell, Benjamin W ^b   Biasucci, Luigi M ^c   Abbate, Antonio ^b  

^a HOSPITAL ITALIANO DE BUENOS AIRES   (Argentina)

^b VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^c UNIVERSITÀ CATTOLICA DEL SACRO CUORE   (Italy)

Author keywords

Biological markers; Inflammation; ST elevation acute myocardial infarction; Ventricular remodeling

Indexed keywords

ADIPONECTIN; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CD14 ANTIGEN; CD16 ANTIGEN; CD40 LIGAND; CHEMOKINE RECEPTOR CCR2; ERYTHROPOIETIN; GALECTIN 3; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; GROWTH DIFFERENTIATION FACTOR 15; INTERLEUKIN 1; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 33; INTERLEUKIN 6; L SELECTIN; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE MIGRATION INHIBITION FACTOR; MATRIX METALLOPROTEINASE; MONOCYTE CHEMOTACTIC PROTEIN 1; MYELOPEROXIDASE; RANTES; STROMAL CELL DERIVED FACTOR 1; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR RECEPTOR 1; TUMOR NECROSIS FACTOR RECEPTOR 2; CHEMOKINE; CYTOKINE;

ADVERSE OUTCOME; CARDIOVASCULAR MORTALITY; CD34 SELECTION; DISEASE MARKER; HEART DEATH; HEART FAILURE; HEART INFARCTION SIZE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART MUSCLE REPERFUSION; HEART VENTRICLE FUNCTION; HEART VENTRICLE REMODELING; HUMAN; INFLAMMATION; LEUKOCYTE COUNT; LEUKOCYTOSIS; LYMPHOCYTOPENIA; MEMBRANE MICROPARTICLE; NEUTROPHIL LYMPHOCYTE RATIO; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; STEM CELL; BLOOD; IMMUNOLOGY; PATHOLOGY;

BIOMARKERS; CHEMOKINES; CYTOKINES; HUMANS; LEUKOCYTE COUNT; PROGNOSIS; ST ELEVATION MYOCARDIAL INFARCTION; VENTRICULAR REMODELING;

EID: 85016122969     PISSN: 20488726     EISSN: 20488734     Source Type: Journal    
DOI: 10.1177/2048872615568965     Document Type: Review

References (214)

1. National Heart Lung and Blood Institute. Morbidity and mortality: 2012 chart book on cardiovascular and lung diseases. Bethesda, MD: NIH, 2012.
2. O’Gara PT, Kushner FG, Ascheim DD, et al. 2013 ACCF/ AHA guideline for the management of ST-elevation myocardial infarction: A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2013; 127 (4): e362–e425.
3. Steg PG, James SK, Atar D, et al. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC). Eur Heart J 2012; 33 (20): 2569–2619.
4. Pfeffer JM, Pfeffer MA and Braunwald E. Influence of chronic captopril therapy on the infarcted left ventricle of the rat. Circ Res 1985; 57: 84–95.
5. Cohn JN, Ferrari R and Sharpe N. Cardiac remodeling— concepts and clinical implications: A consensus paper from an international forum on cardiac remodeling. J Am Coll Cardiol 2000; 35 (3): 569–582.
6. St John, Sutton M, Pfeffer M, Plappert T, et al. Quantitative two-dimensional echocardiographic measurements are major predictors of adverse cardiovascular events after acute myocardial infarction. The protective effects of captopril. Circulation 1994; 89 (1): 68–75.
7. White H, Norris R, Brown M, et al. Left ventricular endsystolic volume as the major determinant of survival after recovery from myocardial infarction. Circulation 1987; 76 (1): 44–51.
8. Jessup M and Brozena S. Heart failure. N Engl J Med 2003; 348 (20): 2007–2018.
9. Goldberg RJ, Spencer FA, Yarzebski J, et al. A 25-year perspective into the changing landscape of patients hospitalized with acute myocardial infarction (the Worcester Heart Attack Study). Am J Cardiol 2004; 94 (11): 1373–1378.
10. Velagaleti RS, Pencina MJ, Murabito JM, et al. Long-term trends in the incidence of heart failure after myocardial infarction. Circulation 2008; 118 (20): 2057–2062.
11. Chew DP, Huynh LT, Liew D, et al. Potential survival gains in the treatment of myocardial infarction. Heart 2009; 95 (22): 1844–1850.
12. Eapen ZJ, Tang WHW, Felker GM, et al. Defining heart failure end points in ST-segment elevation myocardial infarction trials: Integrating past experiences to chart a path forward. Circ Cardiovasc Qual Outcomes 2012; 5 (4): 594–600.
13. Chen J, Hsieh AF-C, Dharmarajan K, et al. National trends in heart failure hospitalization after acute myocardial infarction for medicare beneficiaries: 1998–2010. Circulation 2013; 128 (24): 2577–2584.
14. Hoebers L and Claessen B. Primary percutaneous coronary intervention for ST-segment elevation myocardial infarction in patients with insulin-treated versus non-insulintreated diabetes mellitus. EuroIntervention 2014; 10 (1): 90–96.
15. Frangogiannis NG, Smith CW and Entman ML. The inflammatory response in myocardial infarction. Cardiovasc Res 2002; 53 (1): 31–47.
16. Frangogiannis NG. The immune system and cardiac repair. Pharmacol Res 2008; 58 (2): 88–111.
17. Frangogiannis NG. Regulation of the inflammatory response in cardiac repair. Circ Res 2012; 110 (1): 159–173.
18. Marini MG, Sonnino C, Previtero M, et al. Targeting inflammation: Impact on atherothrombosis. J Cardiovasc Transl Res 2013; 7 (1): 9–18.
19. Seropian I, Toldo S, Van Tassell B, et al. Anti-inflammatory strategies for ST-elevation acute myocardial infarction ventricular remodeling. J Am Coll Cardiol 2014; 63 (16): 1593–1603.
20. Van Tassell BW, Toldo S, Mezzaroma E, et al. Targeting interleukin-1 in heart disease. Circulation 2013; 128 (17): 1910–1923.
21. Abbate A, Van Tassell BW, Biondi-Zoccai G, et al. Effects of interleukin-1 blockade with anakinra on adverse cardiac remodeling and heart failure after acute myocardial infarction [from the virginia commonwealth university-anakinra remodeling trial (2) (VCU-ART2) Pilot Study]. Am J Cardiol 2013; 111 (10): 1394–1400.
22. Ørn S, Manhenke C, Ueland T, et al. C-reactive protein, infarct size, microvascular obstruction, and left-ventricular remodelling following acute myocardial infarction. Eur Heart J 2009; 30 (10): 1180–1186.
23. Suleiman M, Khatib R, Agmon Y, et al. Early inflammation and risk of long-term development of heart failure and mortality in survivors of acute myocardial infarction predictive role of C-reactive protein. J Am Coll Cardiol 2006; 47 (5): 962–968.
24. Bursi F, Weston SA, Killian JM, et al. C-reactive protein and heart failure after myocardial infarction in the community. Am J Med 2006; 120 (7): 616–622.
25. Mather AN, Fairbairn TA, Artis NJ, et al. Relationship of cardiac biomarkers and reversible and irreversible myocardial injury following acute myocardial infarction as determined by cardiovascular magnetic resonance. Int J Cardiol 2013; 166 (2): 458–464.
26. Modan B, Schor S and Shani M. Acute myocardial infarction. Prognostic value of white blood cell count and blood glucose level. JAMA 1975; 233 (3): 266–267.
27. Menon V, Lessard D, Yarzebski J, et al. Leukocytosis and adverse hospital outcomes after acute myocardial infarction. Am J Cardiol 2003; 92 (4): 368–372.
28. Qian G, Wu C, Chen Y-D, et al. Predictive factors of cardiac rupture in patients with ST-elevation myocardial infarction. J Zhejiang Univ Sci B 2014; 15 (12): 1048–1054.
29. Chung S, Song YB, Hahn J-Y, et al. Impact of white blood cell count on myocardial salvage, infarct size, and clinical outcomes in patients undergoing primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: A magnetic resonance imaging study. Int J Cardiovasc Imaging 2014; 30 (1): 129–136.
30. Barron HV, Cannon CP, Murphy SA, et al. Association between white blood cell count, epicardial blood flow, myocardial perfusion, and clinical outcomes in the setting of acute myocardial infarction: A thrombolysis in myocardial infarction 10 substudy. Circulation 2000; 102 (19): 2329–2334.
31. Palmerini T, Mehran R, Dangas G, et al. Impact of leukocyte count on mortality and bleeding in patients with myocardial infarction undergoing primary percutaneous coronary interventions: Analysis from the harmonizing outcome with revascularization and Stent in Acute Myocardial Infarction trial. Circulation 2011; 123 (24): 2829–2837.
32. Palmerini T, Brener SJ, Genereux P, et al. Relation between white blood cell count and final infarct size in patients with ST-segment elevation acute myocardial infarction undergoing primary percutaneous coronary intervention (from the INFUSE AMI Trial). Am J Cardiol 2013; 112 (12): 1860–1866.
33. Kyne L, Hausdorff JM, Knight E, et al. Neutrophilia and congestive heart failure after acute myocardial infarction. Am Heart J 2000; 139 (1): 94–100.
34. Tamura A, Watanabe T and Nasu M. Association between neutrophil counts on admission and left ventricular function in patients successfully anterior wall acute myocardial infarction. Am J Cardiol 2001; 88 (01): 678–680.
35. Husser O, Bodi V, Sanchis J, et al. White blood cell subtypes after STEMI: Temporal evolution, association with cardiovascular magnetic resonance—Derived infarct size and impact on outcome. Inflammation 2011; 34 (2): 73–84.
36. Maekawa Y, Anzai T, Yoshikawa T, et al. Prognostic significance of peripheral monocytosis after reperfused acute myocardial infarction: A possible role for left ventricular remodeling. J Am Coll Cardiol 2002; 39 (2): 241–246.
37. Tsujioka H, Imanishi T, Ikejima H, et al. Post-reperfusion enhancement of CD14+CD16− monocytes and microvascular obstruction in ST-segment elevation acute myocardial infarction. Circ J 2010; 74 (6): 1175–1182.
38. Ikejima H, Imanishi T, Tsujioka H, et al. Effect of human peripheral monocyte subsets on coronary flow reserve in infarct-related artery in patients with primary anterior acute myocardial infarction. Clin Exp Pharmacol Physiol 2010; 37 (4): 453–459.
39. Tsujioka H, Imanishi T, Ikejima H, et al. Impact of heterogeneity of human peripheral blood monocyte subsets on myocardial salvage in patients with primary acute myocardial infarction. J Am Coll Cardiol 2009; 37 (2): 130–138.
40. Tapp LD, Shantsila E, Wrigley BJ, et al. The CD14++CD16+ monocyte subset and monocyte–platelet interactions in patients with ST-elevation myocardial infarction. J Thromb Haemost 2009; 10 (7): 1231–1241.
41. Wrigley BJ, Shantsila E, Tapp LD, et al. CD14++CD16+ monocytes in patients with acute ischaemic heart failure. Eur J Clin Invest 2013; 10 (2): 121–130.
42. Bodí V, Sanchis J, Núñez J, et al. Post-reperfusion lymphopenia and microvascular obstruction in ST-segment elevation acute myocardial infarction. Rev Esp Cardiol 2009; 62 (10): 1109–1117.
43. Núñez J, Núñez E, Bodí V, et al. Low lymphocyte count in acute phase of ST-segment elevation myocardial infarction predicts long-term recurrent myocardial infarction. Coron Artery Dis 2013; 21 (1): 1–7.
44. Núñez J, Núñez E, Bodí V, et al. Usefulness of the neutrophil to lymphocyte ratio in predicting long-term mortality in ST segment elevation myocardial infarction. Am J Cardiol 2008; 101 (6): 747–752.
45. Cho KH, Jeong MH, Ahmed K, et al. Value of early risk stratification using hemoglobin level and neutrophil-tolymphocyte ratio in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention. Am J Cardiol 2011; 107 (6): 849–856.
46. Akpek M, Kaya MG, Lam YY, et al. Relation of neutrophil/ lymphocyte ratio to coronary flow to in-hospital major adverse cardiac events in patients with ST-elevated myocardial infarction undergoing primary coronary intervention. Am J Cardiol 2011; 110 (5): 621–627.
47. Sen N, Afsar B, Ozcan F, et al. The neutrophil to lymphocyte ratio was associated with impaired myocardial perfusion and long term adverse outcome in patients with ST-elevated myocardial infarction undergoing primary coronary intervention. Atherosclerosis 2013; 228 (1): 203–210.
48. Sawant A and Adhikari P. Neutrophil to lymphocyte ratio predicts short and long term mortality following revascularization therapy for ST elevation myocardial infarction. Cardiol J 2013; 21 (5): 500–508.
49. Arbel Y, Shacham Y, Ziv-Baran T, et al. Higher neutrophil/ lymphocyte ratio is related to lower ejection fraction and higher long-term all-cause mortality in ST-elevation myocardial infarction patients. Can J Cardiol 2014; 30 (10): 1177–1182.
50. Ghaffari S, Nadiri M, Pourafkari L, et al. The predictive value of total neutrophil count and neutrophil/lymphocyte ratio in predicting in-hospital mortality and complications after STEMI. J Thorac Cardiovasc Surg 2014; 6 (1): 35–41.
51. He J, Li J, Wang Y, Hao P, et al. Neutrophil-to-lymphocyte ratio (NLR) predicts mortality and adverse-outcomes after ST-segment elevation myocardial infarction in Chinese people. Int J Clin Exp Pathol 2014; 7 (7): 4045–4056.
52. Han Y-C, Yang T-H, Kim D-I, et al. Neutrophil to lymphocyte ratio predicts long-term clinical outcomes in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. Korean Circ J 2013; 43 (2): 93–99.
53. Niccoli G, Burzotta F, Galiuto L, et al. Myocardial no-reflow in humans. J Am Coll Cardiol 2011; 54 (4): 281–292.
54. Soylu K, Yuksel S, Gulel O, et al. The relationship of coronary flow to neutrophil/lymphocyte ratio in patients undergoing primary percutaneous coronary intervention. J Thorac Dis 2013; 5 (3): 258–264.
55. Dogan M, Akyel A, Bilgin M, et al. Can admission neutrophil to lymphocyte ratio predict infarct-related artery patency in ST-segment elevation myocardial infarction. Clin Appl Thromb Hemost 2013.
56. Kurtul A, Murat SN, Yarlioglues M, et al. The relationship between neutrophil/lymphocyte ratio and infarct-related artery patency before mechanical reperfusion in patients with ST-elevation myocardial infarction. Coron Artery Dis 2014; 25 (2): 159–166.
57. Erkol A, Oduncu V, Turan B, et al. Neutrophil to lymphocyte ratio in acute ST-segment elevation myocardial infarction. Am J Med Sci 2014; 348 (1): 37–42.
58. Ayça B, Akın F, Celik O, et al. Neutrophil to lymphocyte ratio is related to stent thrombosis and high mortality in patients with acute myocardial infarction. Angiology 2014.
59. Kaya A, Kaya Y, Topçu S, et al. Neutrophil-to-lymphocyte ratio predicts contrast-induced nephropathy in patients undergoing primary percutaneous coronary intervention. Angiology 2014; 65 (1): 51–56.
60. Yilmaz A, Dietel B, Cicha I, et al. Emergence of dendritic cells in the myocardium after acute myocardial infarction-Implications for inflammatory myocardial damage. Int J Biomed Sci 2010; 6 (1): 27–36.
61. Kretzschmar D, Betge S, Windisch A, et al. Recruitment of circulating dendritic cell precursors into the infarcted myocardium and pro-inflammatory response in acute myocardial infarction. Clin Sci 2012; 123 (6): 387–398.
62. Kofler S, Sisic Z, Shvets N, et al. Expression of circulatory dendritic cells and regulatory T-cells in patients with different subsets of coronary artery disease. J Cardiovasc Pharmacol 2012; 57 (5): 542–549.
63. Yilmaz A, Weber J, Cicha I, et al. Decrease in circulating myeloid dendritic cell precursors in coronary artery disease. J Am Coll Cardiol 2012; 48 (1): 70–80.
64. Montagnana M and Cervellin G. The role of red blood cell distribution width in cardiovascular and thrombotic disorders. Clin Chem Lab Med 2012; 50 (4): 635–641.
65. Karabulut A, Uyarel H, Uzunlar B, et al. Elevated red cell distribution width level predicts worse postinterventional thrombolysis in myocardial infarction flow reflecting abnormal reperfusion in acute myocardial infarction treated with a primary coronary intervention. Coron Artery Dis 2012; 23 (1): 68–72.
66. Sangoi MB, Da Silva SH, da Silva JEP, et al. Relation between red blood cell distribution width and mortality after acute myocardial infarction. Int J Cardiol 2011; 146 (2): 450–454.
67. İlhan E, Güvenç TS, Altay S, et al. Predictive value of red cell distribution width in intrahospital mortality and postintervention thrombolysis in myocardial infarction flow in patients with acute anterior myocardial infarction. Coron Artery Dis 2012; 23 (7): 450–454.
68. Dabbah S, Hammerman H, Markiewicz W, et al. Relation between red cell distribution width and clinical outcomes after acute myocardial infarction. Am J Cardiol 2010; 105 (3): 312–317.
69. Uyarel H, Ergelen M, Cicek G, et al. Red cell distribution width as a novel prognostic marker in patients undergoing primary angioplasty for acute myocardial infarction. Coron Artery Dis 2011; 22 (3): 138–144.
70. Lee JH, Yang DH, Jang SY, et al. Incremental predictive value of red cell distribution width for 12-month clinical outcome after acute myocardial infarction. Clin Cardiol 2013; 36 (6): 336–341.
71. Sun X, Chen W, Sun Z, et al. Impact of red blood cell distribution width on long-term mortality in patients with ST-elevation myocardial infarction. Cardiology 2014; 128 (4): 343–348.
72. Arbel Y, Shacham Y, Finkelstein A, et al. Red blood cell distribution width (RDW) and long-term survival in patients with ST elevation myocardial infarction. Thromb Res 2014; 134 (5): 976–979.
73. Mizuno A, Ohde S, Nishizaki Y, et al. Additional value of the red blood cell distribution width to the Mehran risk score for predicting contrast-induced acute kidney injury in patients with ST-elevation acute myocardial infarction. J Cardiol 2014.
74. Jakob P and Landmesser U. Current status of cell-based therapy for heart failure. Curr Heart Fail Rep 2012; 10 (2): 165–176.
75. Wojakowski W, Kucia M, Kaźmierski M, et al. Circulating progenitor cells in stable coronary heart disease and acute coronary syndromes: Relevant reparatory mechanism? Heart 2008; 10 (1): 27–33.
76. Porto I, De Maria GL, Leone AM, et al. Endothelial progenitor cells, microvascular obstruction, and left ventricular remodeling in patients with ST elevation myocardial infarction undergoing primary percutaneous coronary intervention. Am J Cardiol 2013; 112 (6): 782–791.
77. Shintani S, Murohara T, Ikeda H, et al. Mobilization of endothelial progenitor cells in patients with acute myocardial infarction. Circulation 2001; 103 (23): 2776–2779.
78. Massa M, Rosti V, Ferrario M, et al. Increased circulating hematopoietic and endothelial progenitor cells in the early phase of acute myocardial infarction. Blood 2005; 105 (1): 199–206.
79. Grøgaard HK, Solheim S, Landsverk KS, et al. Circulating CD34+ progenitor cells and growth factors in patients treated with PCI for acute myocardial infarction or stable angina pectoris. Scand J Clin Lab Invest 2011; 71 (4): 322-329.
80. Mariani M, De Servi S, Chianese R, et al. Circulating CD34-positive cell number is related to effective myocardial reperfusion in acute myocardial infarction treated with primary coronary angioplasty. J Cardiovasc Med 2008; 9 (7): 677–682.
81. Leone AM, Rutella S, Bonanno G, et al. Mobilization of bone marrow-derived stem cells after myocardial infarction and left ventricular function. Eur Heart J 2005; 26 (12): 1196–1204.
82. Wang Y, Johnsen HE, Mortensen S, et al. Changes in circulating mesenchymal stem cells, stem cell homing factor, and vascular growth factors in patients with acute ST elevation myocardial infarction treated with primary percutaneous coronary intervention. Heart 2006; 92 (6): 768–774.
83. Gaspardone A, Menghini F, Mazzuca V, et al. Progenitor cell mobilisation in patients with acute and chronic coronary artery disease. Heart 2006; 92 (2): 253–254.
84. Geisler T, Fekecs L, Wurster T, et al. Association of platelet-SDF-1 with hemodynamic function and infarct size using cardiac MR in patients with AMI. Eur J Radiol 2012; 81 (4): e486–e490.
85. Jeong HS, Hong SJ, Park JH, et al. Correlation between circulating angiogenic cell mobilizations and recovery of coronary flow reserve in patients with acute myocardial infarction. Circ J 2012; 76 (5): 1213–1221.
86. Grąbczewska Z, Dębski R, Góralczyk K, et al. Does mobilisation of CD34+ stem cells along with VEGF, angiogenin, IL-6, IL-8, and hsCRP levels allow predicting the direction of left ventricular ejection fraction and wall motion score index changes in patients with myocardial infarction? Kardiol Pol 2013; 71 (5): 464–471.
87. Wojakowski W, Tendera M, Zebzda A, et al. Mobilization of CD34 (+), CD117 (+), CXCR4 (+), c-met (+) stem cells is correlated with left ventricular ejection fraction and plasma NT-proBNP levels in patients with acute myocardial infarction. Eur Heart J 2006; 27 (3): 283–289.
88. Wyderka R, Wojakowski W, Jadczyk T, et al. Mobilization of CD34+CXCR4+ stem/progenitor cells and the parameters of left ventricular function and remodeling in 1-year follow-up of patients with acute myocardial infarction. Mediat Inflamm 2012; 2012: 1–11.
89. Yu CW, Choi S-C, Hong SJ, et al. Cardiovascular event rates in patients with ST-elevation myocardial infarction were lower with early increases in mobilization of Oct4 (high) Nanog (high) stem cells into the peripheral circulation during a 4-year follow-up. Int J Cardiol 2013; 168 (3): 2533–2539.
90. Chang L, Yuen C, Sun C, et al. Role of stromal cell-derived factor-1α, level and value of circulating interleukin-10 and endothelial progenitor cells in patients with acute myocardial infarction undergoing primary coronary angioplasty. Circ J 2009; 73 (6): 1097–1104.
91. Chang H-W, Leu S, Sun C-K, et al. Level and value of circulating endothelial progenitor cells in patients with acute myocardial infarction undergoing primary coronary angioplasty: In vivo and in vitro studies. Transl Res 2010; 156 (4): 251–63.
92. Werner N, Kosiol S, Schiegl T, et al. Circulating endothelial progenitor cells and cardiovascular outcomes. N Engl J Med 2005; 353 (10): 999–1007.
93. Niccoli G, Dato I and Crea F. Myeloperoxidase may help to differentiate coronary plaque erosion from plaque rupture in patients with acute coronary syndromes. Trends Cardiovasc Med 2010; 20 (8): 276–281.
94. Khan SQ, Kelly D, Quinn P, et al. Myeloperoxidase aids prognostication together with N-terminal pro-B-type natriuretic peptide in high-risk patients with acute ST elevation myocardial infarction. Heart 2007; 93 (8): 826–831.
95. Stankovic S, Asanin M, Trifunovic D, et al. Time-dependent changes of myeloperoxidase in relation to in-hospital mortality in patients with the first anterior ST-segment elevation myocardial infarction treated by primary percutaneous coronary intervention. Clin Biochem 2012; 45 (7–8): 547-551.
96. Nilsson L, Hallén J, Atar D, et al. Early measurements of plasma matrix metalloproteinase-2 predict infarct size and ventricular dysfunction in ST-elevation myocardial infarction. Heart 2012; 98 (1): 31–36.
97. Dominguez-Rodriguez A, Samimi-Fard S, Abreu-Gonzalez P, et al. Prognostic value of admission myeloperoxidase levels in patients with ST-segment elevation myocardial infarction and cardiogenic shock. Am J Cardiol 2008; 101 (11): 1537–1540.
98. Stankovic S and Asanin M. The usefulness of myeloperoxidase in prediction of in-hospital mortality in patients with ST-segment elevation myocardial infarction treated by primary percutaneous. Clin Lab 2011; 58 (1–2): 125–131.
99. Kaya MG, Yalcin R, Okyay K, et al. Potential role of plasma myeloperoxidase level in predicting long-term outcome of acute myocardial infarction. Tex Heart Inst J 2012; 39 (4): 500–506.
100. Marshall CJ, Nallaratnam M, Mocatta T, et al. Factors influencing local and systemic levels of plasma myeloperoxidase in ST-segment elevation acute myocardial infarction. Am J Cardiol 2010; 106 (3): 316–322.
101. Dinarello CA. Interleukin-1 in the pathogenesis and treatment of inflammatory diseases. Blood 2011; 117 (14): 3720–3732.
102. Bujak M and Frangogiannis NG. The role of IL-1 in the pathogenesis of heart disease. Arch Immunol Ther Exp 2009; 57 (3): 165–176.
103. Biasucci LM, Liuzzo G, Fantuzzi G, et al. Increasing levels of interleukin (IL)-1Ra and IL-6 during the first 2 days of hospitalization in unstable angina are associated with increased risk of in-hospital coronary events. Circulation 1999; 99 (16): 2079–2084.
104. Guillen I, Blanes M, Castell JV, et al. Cytokine signaling during myocardial infarction: Sequential appearance of IL-1 beta and IL-6 cytokine signaling during myocardial infarction: Sequential appearance of ILAp and IL-6. Am J Physiol 1995; 269 (2): 229–235.
105. Ørn S, Ueland T, Manhenke C, et al. Increased interleukin-1β levels are associated with left ventricular hypertrophy and remodelling following acute ST segment elevation myocardial infarction treated by primary percutaneous coronary intervention. J Intern Med 2012; 272 (3): 267–276.
106. Patti G, Mega S, Pasceri V, et al. Interleukin-1 receptor antagonist levels correlate with extent of myocardial loss in patients with acute myocardial infarction. Clin Cardiol 2005; 28 (4): 193–196.
107. Shimpo M, Morrow DA, Weinberg EO, et al. Serum levels of the interleukin-1 receptor family member ST2 predict mortality and clinical outcome in acute myocardial infarction. Circulation 2004; 109 (18): 2186–2190.
108. Sabatine MS, Morrow DA, Higgins LJ, et al. Complementary roles for biomarkers of biomechanical strain ST2 and N-terminal prohormone B-type natriuretic peptide in patients with ST-elevation myocardial infarction. Circulation 2008; 117 (15): 1936–1944.
109. Dhillon OS, Narayan HK, Khan SQ, et al. Pre-discharge risk stratification in unselected STEMI: Is there a role for ST2 or its natural ligand IL-33 when compared with contemporary risk markers? Int J Cardiol 2013; 167 (5): 2182–2188.
110. Weir RA, Miller AM, Murphy GE, et al. Serum soluble ST2: A potential novel mediator in left ventricular and infarct remodeling after acute myocardial infarction. J Am Coll Cardiol 2010; 55 (3): 243–250.
111. Yamamoto K and Rose-John S. Therapeutic blockade of interleukin-6 in chronic inflammatory disease. Clin Pharmacol Ther 2012; 91 (4): 574–576.
112. Lindmark E and Diderholm E. Relationship between interleukin 6 and mortality in patients with unstable coronary artery disease. JAMA 2001; 286 (17): 2107–2113.
113. Di Stefano R, Di Bello V, Barsotti MC, et al. Inflammatory markers and cardiac function in acute coronary syndrome: Difference in ST-segment elevation myocardial infarction (STEMI) and in non-STEMI models. Biomed Pharmacother 2009; 63 (10): 773–780.
114. Hartford M, Wiklund O, Mattsson Hultén L, et al. CRP, interleukin-6, secretory phospholipase A2 group IIA, and intercellular adhesion molecule-1 during the early phase of acute coronary syndromes and long-term follow-up. Int J Cardiol 2006; 108 (1): 55–62.
115. Prondzinsky R, Unverzagt S, Lemm H, et al. Interleukin-6,-7,-8 and-10 predict outcome in acute myocardial infarction complicated by cardiogenic shock. Clin Res Cardiol 2012; 101 (5): 375–384.
116. Hartford M, Wiklund O, Mattsson Hultén L, et al. C-reactive protein, interleukin-6, secretory phospholipase A2 group IIA and intercellular adhesion molecule-1 in the prediction of late outcome events after acute coronary syndromes. J Intern Med 2007; 262 (5): 526–536.
117. Théroux P, Armstrong PW, Mahaffey KW, et al. Prognostic significance of blood markers of inflammation in patients with ST-segment elevation myocardial infarction undergoing primary angioplasty and effects of pexelizumab, a C5 inhibitor: A substudy of the COMMA trial. Eur Heart J 2005; 26 (19): 1964–1970.
118. Van Diepen S, Newby LK, Lopes RD, et al. Prognostic relevance of baseline pro-and anti-inflammatory markers in STEMI: An APEX AMI substudy. Inflammation 2013; 168 (3): 2127–2133.
119. Tan J, Hua Q, Gao J, et al. Clinical implications of elevated serum interleukin-6, soluble CD40 ligand, metalloproteinase-9, and tissue inhibitor of metalloproteinase-1 in patients with acute ST-segment elevation myocardial infarction. Clin Cardiol 2008; 31 (9): 413–418.
120. Tan J, Hua Q, Li J, et al. Prognostic value of interleukin-6 during a 3-year follow-up in patients with acute ST-segment elevation myocardial infarction. Heart Vessel 2009; 24 (5): 329–334.
121. Kavsak PA, Ko DT, Newman AM, et al. Risk stratification for heart failure and death in an acute coronary syndrome population using inflammatory cytokines and N-terminal pro-brain natriuretic peptide. Clin Chem 2007; 53 (12): 2112–2118.
122. Halvorsen S, Seljeflot I, Weiss T, et al. Inflammatory and thrombotic markers in patients with ST-elevation myocardial infarction treated with thrombolysis and early PCI: A NORDISTEMI substudy. Thromb Res 2012; 130 (3): 495-500.
123. Borrayo-Sánchez G. Prognostic value of serum levels of interleukin-6 in patients with ST-segment elevation acute myocardial infarction. Cir Cir 2010; (1): 25–30.
124. Ohtsuka T, Hamada M, Inoue K, et al. Relation of circulating interleukin-6 to left ventricular remodeling in patients with reperfused anterior myocardial infarction. Clin Cardiol 2004; 27 (7): 417–420.
125. Frangogiannis NG. The mechanistic basis of infarct healing. Antioxid Redox Signal 2006; 8: 1907–1939.
126. Nilsson L, Szymanowski A, Swahn E, et al. Soluble TNF receptors are associated with infarct size and ventricular dysfunction in ST-elevation myocardial infarction. PLoS One 2013; 8 (2): e55477.
127. Karpiński L, Płaksej R, Kosmala W, et al. Serum levels of interleukin-6, interleukin-10 and C-reactive protein in relation to left ventricular function in patients with myocardial infarction treated with primary angioplasty. Kardiolo Pol 2008; 66 (12): 1279–1285.
128. Dominguez-Rodriguez A, Abreu-Gonzalez P, Garcia-Gonzalez MJ, et al. Soluble CD40 ligand: interleukin-10 ratio predicts in-hospital adverse events in patients with ST-segment elevation myocardial infarction. Thromb Res 2007; 121 (3): 293–299.
129. Appa Falcao R, Christopher S, Oddi C, et al. Interleukin-10 in patients with ST-segment elevation myocardial infarction. Int J Cardiol 2014; 172 (1): e6–e8.
130. Kempf T, Zarbock A, Widera C, et al. GDF-15 is an inhibitor of leukocyte integrin activation required for survival after myocardial infarction in mice. Nat Med 2011; 17 (5): 581–588.
131. Kempf T, Björklund E, Olofsson S, et al. Growth differentiation factor-15 improves risk stratification in ST-segment elevation myocardial infarction. Eur Heart J 2007; 28 (23): 2858–2865.
132. Eitel I, Blase P, Adams V, et al. Growth-differentiation factor 15 as predictor of mortality in acute reperfused ST-elevation myocardial infarction: Insights from cardiovascular magnetic resonance. Heart 2011; 97 (8): 632–640.
133. Lin J-F, Wu S, Hsu S-Y, et al. Growth-differentiation factor-15 and major cardiac events. Am J Med Sci 2014; 347 (4): 305–311.
134. Biasucci LM. CDC/AHA workshop on markers of inflammation and cardiovascular disease: Application to clinical and public health practice: Clinical use of inflammatory markers in patients with cardiovascular diseases: A background paper. Circulation 2004; 110 (25): e560–e567.
135. Matsumori A, Furukawa Y, Hashimoto T, et al. Plasma levels of the monocyte chemotactic and activating factor/monocyte chemoattractant protein-1 are elevated in patients with acute myocardial infarction. J Mol Cell Cardiol 1997; 29 (1): 419–423.
136. Parissis JT, Adamopoulos S, Venetsanou KF, et al. Serum profiles of C-C chemokines in acute myocardial infarction: Possible implication in postinfarction left ventricular remodeling. J Interferon Cytokine Res 2002; 22 (2): 223-229.
137. Kobusiak-Prokopowicz M, Orzeszko J, Mazur G, et al. Chemokines and left ventricular function in patients with acute myocardial infarction. Eur J Intern Med 2007; 18 (4): 288–294.
138. Buyukkaya E, Poyraz F, Karakas MF, et al. Usefulness of monocyte chemoattractant protein-1 to predict no-reflow and three-year mortality in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. Am J Cardiol 2013; 112 (2): 187–193.
139. Zernecke A, Bernhagen J and Weber C. Macrophage migration inhibitory factor in cardiovascular disease. Circulation 2008; 117 (12): 1594–1602.
140. Yu C, Lau C and Lai K. Elevation of plasma level of macrophage migration inhibitory factor in patients with acute myocardial infarction. Am J Cardiol 2001; 88 (7): 774–777.
141. Yu C-M, Lai KW-H, Chen Y-X, et al. Expression of macrophage migration inhibitory factor in acute ischemic myocardial injury. J Histochem Cytochem 2003; 51 (5): 625–631.
142. Takahashi M, Nishihira J, Katsuki T, et al. Elevation of plasma level of macrophage migration inhibitory factor in patients with acute myocardial infarction. Am J Cardiol 2002; 89 (2): 248–249.
143. White DA, Fang L, Chan W, et al. Pro-inflammatory action of MIF in acute myocardial infarction via activation of peripheral blood mononuclear cells. PLoS One 2013; 8 (10): e76206.
144. Chan W, White DA, Wang X-Y, et al. Macrophage migration inhibitory factor for the early prediction of infarct size. J Am Heart Assoc 2013; 2 (5): e000226.
145. Steppich BA, Moog P, Matissek C, et al. Cytokine profiles and T cell function in acute coronary syndromes. Atherosclerosis 2007; 190 (2): 443–451.
146. Stellos K, Ruf M, Sopova K, et al. Plasma levels of stromal cell-derived factor-1 in patients with coronary artery disease: Effect of clinical presentation and cardiovascular risk factors. Atherosclerosis 2011; 219 (2): 913–916.
147. Yousuf O, Mohanty BD, Martin SS, et al. High-sensitivity C-reactive protein and cardiovascular disease: A resolute belief or an elusive link? J Am Coll Cardiol 2013; 62 (5): 397–408.
148. Anzai T. Post-infarction inflammation and left ventricular remodeling: A double-edged sword. Circ J 2013; 77 (3): 580–587.
149. Morishima I, Sone T, Tsuboi H, et al. Plasma C-reactive protein predicts left ventricular remodeling and function after a first acute anterior wall myocardial infarction treated with coronary angioplasty: Comparison with brain natriuretic peptide. Clin Cardiol 2002; 25 (3): 112–116.
150. Roubille F, Samri A, Cornillet L, et al. Routinely-feasible multiple biomarkers score to predict prognosis after revascularized STEMI. Eur J Intern Med 2010; 21 (2): 131–136.
151. Anzai T, Yoshikawa T, Shiraki H, et al. C-reactive protein as a predictor of infarct expansion and cardiac rupture after a first Q-wave acute myocardial infarction. Circulation 1997; 96 (3): 778–784.
152. Suleiman M, Aronson D, Reisner SA, et al. Admission C-reactive protein levels and 30-day mortality in patients with acute myocardial infarction. Am J Med 2003; 115 (9): 695–701.
153. Ohlmann P, Jaquemin L, Morel O, et al. Prognostic value of C-reactive protein and cardiac troponin I in primary percutaneous interventions for ST-elevation myocardial infarction. Am Heart J 2006; 152 (6): 1161–1167.
154. Scirica BM, Morrow DA, Cannon CP, et al. Clinical application of C-reactive protein across the spectrum of acute coronary syndromes. Clin Chem 2007; 53 (10): 1800–1807.
155. Smit JJ, Ottervanger JP, Slingerland RJ, et al. Comparison of usefulness of C-reactive protein versus white blood cell count to predict outcome after primary percutaneous coronary intervention for ST elevation myocardial infarction. Am J Cardiol 2008; 101 (4): 446–451.
156. Derzhko R, Plaksej R, Przewlocka-Kosmala M, et al. Prediction of left ventricular dysfunction progression in patients with a first ST-elevation myocardial infarction— Contribution of cystatin C assessment. Coron Artery Dis 2009; 20 (7): 453–461.
157. Fertin M, Hennache B, Hamon M, et al. Usefulness of serial assessment of B-type natriuretic peptide, troponin I, and C-reactive protein to predict left ventricular remodeling after acute myocardial infarction (from the REVE-2 study). Am J Cardiol 2010; 106 (10): 1410–1416.
158. Urbano-Moral JA, Lopez-Haldon JE, Fernandez M, et al. Prognostic value of different serum biomarkers for left ventricular remodelling after ST-elevation myocardial infarction treated with primary percutaneous coronary intervention. Heart 2012; 98 (15): 1153–1159.
159. Swiatkiewicz I, Kozinski M, Magielski P, et al. Value of C-reactive protein in predicting left ventricular remodelling in patients with a first ST-segment elevation myocardial infarction. Mediat Inflamm 2012: 1–11.
160. Swiatkiewicz I, Kozinski M, Magielski P, et al. Usefulness of C-reactive protein as a marker of early post-infarct left ventricular systolic dysfunction. Inflamm Res 2012; 61 (7): 725–734.
161. Vrsalovic M, Pintaric H, Babic Z, et al. Impact of admission anemia, C-reactive protein and mean platelet volume on short term mortality in patients with acute ST-elevation myocardial infarction treated with primary angioplasty. Clin Biochem 2012; 45 (16–17): 1506–1509.
162. Schoos MM, Munthe-Fog L, Skjoedt M-O, et al. Association between lectin complement pathway initiators, C-reactive protein and left ventricular remodeling in myocardial infarction-a magnetic resonance study. Mol Immunol 2013; 54 (3–4): 408–414.
163. Marcucci R, Valente S, Gori AM, et al. Global platelet hyperreactivity and elevated C-reactive protein levels predict long term mortality in STEMI patients. Thromb Res 2014; 134 (4): 884–888.
164. Shacham Y, Leshem-Rubinow E, Steinvil A, et al. High sensitive C-reactive protein and the risk of acute kidney injury among ST elevation myocardial infarction patients undergoing primary percutaneous intervention. Clin Exp Neprhol 2014.
165. Biasucci LM, Liuzzo G, Grillo RL, et al. Elevated levels of C-reactive protein at discharge in patients with unstable angina predict recurrent instability. Circulation 1999; 99 (7): 855–860.
166. Pepys MB, Hirschfield GM, Tennent GA, et al. Targeting C-reactive protein for the treatment of cardiovascular disease. Nature 2006; 440 (7088): 1217–1221.
167. Biasucci LM, Bellocci F, Landolina M, et al. Risk stratification of ischaemic patients with implantable cardioverter defibrillators by C-reactive protein and a multi-markers strategy: Results of the CAMI-GUIDE study. Eur Heart J 2012; 33 (11): 1344–1350.
168. Abbate A, Kontos MC, Grizzard JD, et al. Interleukin-1 blockade with anakinra to prevent adverse cardiac remodeling after acute myocardial infarction (Virginia Commonwealth University Anakinra Remodeling Trial [VCU-ART] Pilot study). Am J Cardiol 2010; 105 (10): 1371. e1–1377. e1.
169. Morton AC, Rothman AM, Greenwood JP, et al. The effect of interleukin-1 receptor antagonist therapy on markers of inflammation in non-ST elevation acute coronary syndromes: The MRC-ILA Heart Study. Circulation 2013; 128: A14792.
170. Nairz M, Sonnweber T, Schroll A, et al. The pleiotropic effects of erythropoietin in infection and inflammation. Microbes Infect 2012; 14 (3): 238–246.
171. Gao D, Ning N, Niu X, et al. Erythropoietin treatment in patients with acute myocardial infarction: A meta-analysis of randomized controlled trials. Am Heart J 2012; 164 (5): 715. e1–727. e1.
172. Namiuchi S, Kagaya Y, Ohta J, et al. High serum erythropoietin level is associated with smaller infarct size in patients with acute myocardial infarction who undergo successful primary percutaneous coronary intervention. J Am Coll Cardiol 2005; 45 (9): 1406–1412.
173. Niccoli G, Andreotti F, Marzo F, et al. Endogenous serum erythropoietin and no-reflow in patients with ST-elevation myocardial infarction. Eur J Clin Invest 2011; 41 (11): 1210–1219.
174. Szummer K, Lindahl B, Sylvén C, et al. Relationship of plasma erythropoietin to long-term outcome in acute coronary syndrome. Int J Cardiol 2010; 143 (2): 165–170.
175. Barseghian A, Gawande D and Bajaj M. Adiponectin and vulnerable atherosclerotic plaques. J Am Coll Cardiol 2011; 57 (7): 761–770.
176. Kojima S, Funahashi T, Sakamoto T, et al. The variation of plasma concentrations of a novel, adipocyte derived protein, adiponectin, in patients with acute myocardial infarction. Heart 2003; 89 (6): 667.
177. Chen C, Asakura M and Asanuma H. Plasma adiponectin levels predict cardiovascular events in the observational Arita Cohort Study in Japan: The importance of the plasma adiponectin levels. Hypertens Res 2012; 35 (8): 843–848.
178. Krasnodębski P, Opolski G and Karnafel W. Plasma adiponectin levels in acute myocardial infarction and during the postinfarction recovery period in patients with type 2 diabetes mellitus. Kardiol Pol 2011; 69 (9): 924–930.
179. Shibata R, Numaguchi Y, Matsushita K, et al. Usefulness of adiponectin to predict myocardial salvage following successful reperfusion in patients with acute myocardial infarction. Am J Cardiol 2008; 101 (12): 1712–1715.
180. Lindberg S, Pedersen SH, Møgelvang R, et al. Usefulness of adiponectin as a predictor of all cause mortality in patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention. Am J Cardiol 2012; 109 (4): 492–496.
181. Wilson SR, Sabatine MS, Wiviott SD, et al. Assessment of adiponectin and the risk of recurrent cardiovascular events in patients presenting with an acute coronary syndrome: Observations from the Pravastatin Or atorVastatin Evaluation and Infection Trial-Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22). Am Heart J 2009; 161 (6): 1147–1155.
182. Piestrzeniewicz K, Luczak K and Goch J. Value of blood adipose tissue hormones concentration—Adiponectin, resistin and leptin in the prediction of major adverse cardiac events (MACE) in 1-year follow-up after primary percutaneous coronary intervention in ST-segment elevation acute myocardial. Neuro Endocrinol Lett 2008; 29 (4): 581–588.
183. Reinstadler SJ, Klug G, Feistritzer HJ, et al. Relation of plasma adiponectin levels and aortic stiffness after acute ST-segment elevation myocardial infarction. Eur Heart J Acute Cardiovasc Care 2014; 3 (1): 10–17.
184. Morita Y, Maeda K, Kondo T, et al. Impact of adiponectin and leptin on long-term adverse events in Japanese patients with acute myocardial infarction. Circ J 2013; 77 (11): 2778–2785.
185. Shim W, Mehta A, Lim SY, et al. G-CSF for stem cell therapy in acute myocardial infarction: Friend or foe? Cardiovasc Res 2011; 89 (1): 20–30.
186. Leone AM, Rutella S, Bonanno G, et al. Endogenous G-CSF and CD34+ cell mobilization after acute myocardial infarction. Int J Cardiol 2006; 111 (2): 202–208.
187. Ma Y-T and Fu Z-Y. Serum profiles of circulating granulocyte-macrophage colony-stimulating factor in acute myocardial infarction and relation with post-infarction left ventricular function. Chin Med J 2005; 118 (8): 1557–1559.
188. Moazzami K, Roohi A and Moazzami B. Granulocyte colony stimulating factor therapy for acute myocardial infarction (review). Cochrane Database Syst Rev 2013; (5): CD008844.
189. Parissis JT, Adamopoulos S, Venetsanou K, et al. Plasma profiles of circulating granulocyte-macrophage colonystimulating factor and soluble cellular adhesion molecules in acute myocardial infarction. Contribution to post-infarction left ventricular dysfunction. Eur Cytokine Netw 2004; 15 (2): 139–144.
190. Creemers EEJM, Cleutjens JPM, Smits JFM, et al. Matrix metalloproteinase inhibition after myocardial infarction: A new approach to prevent heart failure? Circ Res 2001; 89 (3): 201–210.
191. Gearing A, Beckett P and Christodoulou M. Processing of tumour necrosis factor-α precursor by metalloproteinases. Nature 1994; 370: 555–557.
192. Schönbeck U, Mach F and Libby P. Generation of biologically active IL-1β by matrix metalloproteinases: A novel caspase-1-independent pathway of IL-1β processing. J Immunol 1998; 161: 3340–3346.
193. Tan J and Hua Q. Correlations between serum inflammation factors and left ventricular remodeling in acute ST segment elevation myocardial infarction. Yonsei Med J 2012; 53 (3): 501–507.
194. Webb CS, Bonnema DD, Ahmed SH, et al. Specific temporal profile of matrix metalloproteinase release occurs in patients after myocardial infarction: Relation to left ventricular remodeling. Circulation 2006; 114 (10): 1020-1027.
195. Wagner DR, Delagardelle C, Ernens I, et al. Matrix metalloproteinase-9 is a marker of heart failure after acute myocardial infarction. J Card Fail 2006; 12 (1): 66–72.
196. Kuliczkowski W, Urbaniak J, Hallén J, et al. Matrix metalloproteinases and the activity of their tissue inhibitors in patients with ST-elevation myocardial infarction treated with primary angioplasty. Kardiol Pol 2013; 71 (5): 31–36.
197. Conde ID and Kleiman NS. Soluble CD40 ligand in acute coronary syndromes. N Engl J Med 2003; 348 (25): 2575-2577.
198. Pusuroglu H, Akgul O, Erturk M, et al. Predictive value of elevated soluble CD40 ligand in patients undergoing primary angioplasty for ST-segment elevation myocardial infarction. Coron Artery Dis 2014; 25 (7): 558–564.
199. De Boer RA, Voors AA, Muntendam P, et al. Galectin-3: A novel mediator of heart failure development and progression. Eur J Heart Fail 2009; 11 (9): 811–817.
200. Szadkowska I, Wlazeł RN, Migała M, et al. The association between galectin-3 and clinical parameters in patients with first acute myocardial infarction treated with primary percutaneous coronary angioplasty. Cardiol J 2013; 20 (6): 577–582.
201. Szadkowska I and Wlazel R. The association between galectin-3 and occurrence of reinfarction early after first myocardial infarction treated invasively. Biomarkers 2013; 18 (8): 655–659.
202. Weir RA, Petrie CJ, Murphy CA, et al. Galectin-3 and cardiac function in survivors of acute myocardial infarction. Circ Heart Fail 2013; 6 (3): 492–498.
203. Benameur T, Andriantsitohaina R and Martínez MC. Therapeutic potential of plasma membrane-derived microparticles. Pharmacol Rep 2009; 61 (1): 49–57.
204. Wang J-G, Williams JC, Davis BK, et al. Monocytic microparticles activate endothelial cells in an IL-1β-dependent manner. Blood 2011; 118 (8): 2366–2374.
205. Mallat Z, Benamer H, Hugel B, et al. Elevated levels of shed membrane microparticles with procoagulant potential in the peripheral circulating blood of patients with acute coronary syndromes. Circulation 2000; 101 (8): 841–843.
206. Min P-K, Kim J-Y, Chung K-H, et al. Local increase in microparticles from the aspirate of culprit coronary arteries in patients with ST-segment elevation myocardial infarction. Atherosclerosis 2013; 227 (2): 323–328.
207. Porto I, Biasucci LM, De Maria GL, et al. Intracoronary microparticles and microvascular obstruction in patients with ST elevation myocardial infarction undergoing primary percutaneous intervention. Eur Heart J 2012; 33 (23): 2928–2938.
208. Jung C, Sörensson P, Saleh N, et al. Circulating endothelial and platelet derived microparticles reflect the size of myocardium at risk in patients with ST-elevation myocardial infarction. Atherosclerosis 2012; 221 (1): 226–231.
209. Pearson TA. Markers of inflammation and cardiovascular disease: Application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 2003; 107 (3): 499–511.
210. Biasucci LM, Koenig W, Mair J, et al. How to use C-reactive protein in acute coronary care. Eur Heart J 2013; 34 (48): 3687–3690.
211. Ridker P and Danielson E. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008; 359 (21): 2195–2207.
212. Ridker PM, Thuren T, Zalewski A, et al. Interleukin-1β inhibition and the prevention of recurrent cardiovascular events: Rationale and design of the Canakinumab Antiinflammatory Thrombosis Outcomes Study (CANTOS). Am Heart J 2011; 162 (4): 597–605.
213. Van Tassell BW, Arena R, Biondi-Zoccai G, et al. Effects of interleukin-1 blockade with anakinra on aerobic exercise capacity in patients with heart failure and preserved ejection fraction (from the D-HART Pilot Study). Am J Cardiol 2013; 113 (2): 321–327.
214. Seropian IM, Toldo S, Van Tassell BW, et al. Anti-inflammatory strategies for ventricular remodeling following ST-segment elevation acute myocardial infarction. J Am Coll Cardiol 2014; 63 (16): 1593–1603.